-
New to The Street Show #694 to Broadcast Tonight at 6:30 PM EST as Sponsored Programming on Bloomberg TV Featuring Stardust Power (NASDAQ:SDST), Spartan Equipment, Roadzen (NASDAQ:RDZN), Aeries Techno
-
Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC
-
Acurx receives Australian patent for DNA polymerase IIIC inhibitors
-
New to The Street to Broadcast Tonight on Fox Business 10:30 PM PST Featuring NeOnc Technologies, FLOKI, XION, Sharps Technology, and Aeries Technology
-
New to The Street to Broadcast Nationwide on Bloomberg Tonight at 6:30 PM EST
-
H.C. Wainwright Reiterates Buy Rating on Acurx Pharmaceuticals inc. (ACXP)
-
Acurx receives EMA approval for pediatric plan on C. difficile drug
-
New to The Street to Broadcast Saturday, September 27th Featuring NeOnc Pharma $NTHI and Other Innovative Companies
-
New to The Street to Broadcast Episode 686 Tonight on Bloomberg Television at 6:30 PM EST
-
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events
-
New to The Street T.V. Broadcasting on Bloomberg Saturday Aug 30th. The episode features TON Strategy Company (NASDAQ: TONX), Laser Photonics (NASDAQ: LASE), Sullivan & Cromwell Senior M&A Partner Fra
-
Acurx Pharmaceuticals inc. (ACXP) PT Raised to $31 at H.C. Wainwright
-
Acurx Pharmaceuticals (ACXP) Misses Q2 EPS by 171c
-
Acurx Pharmaceuticals (ACXP) Files for 9.16M Share Offering by Selling Stockholders
-
New to The Street Announces the Broadcast of Show Number 675 This Saturday at 6:30 PM EST on Bloomberg Television Featuring: FLOKI, BioVie (NASDAQ: BIVI), Arrive AI ($ARAI), Health In Tech (NASDAQ HIT
-
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
-
H.C. Wainwright Assumes Acurx Pharmaceuticals inc. (ACXP) at Buy
-
Acurx Pharmaceuticals (ACXP) Tops Q1 EPS by 27c
-
Acurx Pharmaceuticals (ACXP): Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
-
New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach
-
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kev
-
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie’s Dr. Joe Palumbo, The Sustainable Green Team with Kevin
-
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevi
-
Acurx Pharmaceuticals (ACXP) Files for 8.4M Share Offering by Selling Stockholders
-
Acurx Pharmaceuticals (ACXP) Announces 2.745M Share Offering at $0.40/sh
-
Acurx Pharmaceuticals (ACXP) Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
-
Acurx Pharmaceuticals (ACXP) Granted Patent in Japan for DNA Polymerase IIIC Inhibitors
-
New to the Street to Broadcast Show 627 on Bloomberg Television at 6:30 PM EST Today as Sponsored Programming
-
Acurx Pharmaceuticals (ACXP) Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection
-
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
-
Acurx Pharmaceuticals (ACXP) Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications
-
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
-
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
-
Acurx Pharmaceuticals (ACXP) Approves Bitcoin as Treasury Reserve Asset
-
Acurx Pharmaceuticals (ACXP) Misses Q3 EPS by 2c
-
New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable G
-
New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical (NASDAQ:MODD), Acurx Pharmaceuticals (NASDAQ:ACXP), and LightPath Technologies (NASDAQ:LPT
-
Acurx Pharmaceuticals (ACXP) Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference
-
New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support
-
New to the Street Announces Exclusive Bloomberg Lineup for Saturday October 12 at 6:30 PM EST
-
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST
-
Acurx Pharmaceuticals (ACXP) Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax Susceptibility to ACX-375 Analogues
-
Acurx Pharmaceuticals (ACXP) Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
-
New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 10:30 PM PT September 9, 2024 09:15 ET
-
Acurx Pharmaceuticals (ACXP) Misses Q2 EPS by 9c

